Golden
Seres Therapeutics

Seres Therapeutics

Seres Therapeutics is a microbiome therapeutics company that was founded in 2010 and headquartered in Cambridge, Massachusetts.

All edits

Edits on 13 Nov 2019
Carla Faraguna
Carla Faraguna edited on 13 Nov 2019 9:58 pm
Edits made to:
Infobox (+1 properties)
Edits on 11 Sep 2019
Golden AI"Set entity company status to Active"
Golden AI edited on 11 Sep 2019 7:58 pm
Edits made to:
Infobox (--1 properties)

Infobox

Company status
Active
Edits on 11 Apr 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 11 Apr 2019 7:12 pm
Edits made to:
Article (+13/-13 characters)

Article

On November 27, 2012 Seres Therapeutics closed their series A funding round with an undisclosed amount of funding from Flagship Pioneering and Enso VenturesEnso Ventures.

Meredith Hanel
Meredith Hanel approved a suggestion from Golden's AI on 11 Apr 2019 7:04 pm
Edits made to:
Infobox (+1 properties)

Infobox

Industry
Edits on 9 Jan 2019
Golden AI
Golden AI edited on 9 Jan 2019 10:09 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 15 Nov 2018
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 15 Nov 2018 7:56 pm
Edits made to:
Article (+11/-11 characters)

Article

On may 23, 2014 Seres Therapeutics closed their series B funding round with$10 million in funding from Mayo ClinicMayo Clinic, Flagship Pioneering, Enso ventures, and Alexandria Venture. 

Edits on 7 Nov 2018
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 7 Nov 2018 6:46 pm
Edits made to:
Article (+24/-24 characters)

Article

Seres Therapeutics is a microbiome therapeutics company headquartered in Cambridge, MassachusettsCambridge, Massachusetts and was founded in 2010 by Noubar Afeyan and David Berry. Seres Therapeutics is using a discovery and design platform for developing new therapies using live bacteria for the treatment of diseases that are a result of microbiome deficiencies. Seres Therapeutics is focused on developing therapies for the treatment of Clostridium difficile infection (CDI), inflammatory bowel disease, and an oral microbiome therapy for improving the safety and efficacy of immunotherapies. 

Edits on 7 Nov 2018
Dawson Sewell
Dawson Sewell edited on 7 Nov 2018 2:15 pm
Edits made to:
Infobox (+3 properties)
Description (+128/-7 characters)
Article (+1209 characters)
People (+15 rows) (+30 cells) (+852 characters)
Categories (+1 topics)
Related Topics (+2 topics)
Topic thumbnail

Seres Therapeutics

Company

Seres Therapeutics is a microbiome therapeutics company that was founded in 2010 and headquartered in Cambridge, Massachusetts.

Article

Seres Therapeutics is a microbiome therapeutics company headquartered in Cambridge, Massachusetts and was founded in 2010 by Noubar Afeyan and David Berry. Seres Therapeutics is using a discovery and design platform for developing new therapies using live bacteria for the treatment of diseases that are a result of microbiome deficiencies. Seres Therapeutics is focused on developing therapies for the treatment of Clostridium difficile infection (CDI), inflammatory bowel disease, and an oral microbiome therapy for improving the safety and efficacy of immunotherapies. 

Funding

Series A

On November 27, 2012 Seres Therapeutics closed their series A funding round with an undisclosed amount of funding from Flagship Pioneering and Enso Ventures.

Series B

On may 23, 2014 Seres Therapeutics closed their series B funding round with$10 million in funding from Mayo Clinic, Flagship Pioneering, Enso ventures, and Alexandria Venture. 

Series C

On December 2, 2014 Seres Therapeutics closed their series C funding round with $48 million in funding from Flagship Pioneering. 

Series D

On January 6, 2015 Seres Therapeutics closed their series D funding round with $65 million in funding from Nestlé Health Science. 

People

Name
Role
Related Golden topics

Barbara McGovern

Vice President, Medical Affairs



Carlo Tanzi

Vice President, Investor Relations and Corporate Communications



Carol Lewis-Cullinan

Vice President, Clinical Operations



David Berry

Co-Founder



David Cook

Executive Vice President, CSO



Eric Shaff

Executive Vice President, Chief Operating and Financial Officer



Henry Rath

Senior Vice President, Corporate Development



Jeff York

Vice President, Human Resources



Jim Weston

Senior Vice President, Regulatory Affairs



John Aunins

Executive Vice President, Bioprocesses & manufacturing and CTO



Kevin Horgan

Executive Vice President, Chief Medical Officer



Mathew Henn

Executive Vice president, Microbiome Research and Development



Noubar Afeyan

Co-Founder



Roger Pomerantz

President, CEO, and Chairman of the Board of Directors



Thomas DesRosier

Executive Vice President, Chief Legal Officer and Secretary



Infobox

Categories

Related Topics

Edits on 18 Sep 2018
Golden AI"Import data from spreadsheet"
Golden AI edited on 18 Sep 2018 8:00 pm
Edits made to:
Description (+7 characters)
Categories (+1 topics)
Topic thumbnail

Seres Therapeutics

Company

Categories

Edits on 15 Aug 2018
Carla Faraguna"Initial topic creation"
Carla Faraguna created this topic on 15 Aug 2018 10:18 pm
Edits made to:
Topic thumbnail

 Seres Therapeutics

Seres Therapeutics is a microbiome therapeutics company that was founded in 2010 and headquartered in Cambridge, Massachusetts.

No more activity to show.